Unit of Mycology and Parasitology (43/117), Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark.
Antimicrob Agents Chemother. 2011 May;55(5):1891-5. doi: 10.1128/AAC.01373-10. Epub 2011 Feb 28.
Disk diffusion testing has recently been standardized by the CLSI, and susceptibility breakpoints have been established for several antifungal compounds. For caspofungin, 5-μg disks are approved, and for micafungin, 10-μg disks are under evaluation. We evaluated the performances of caspofungin and micafungin disk testing using a panel of Candida isolates with and without known FKS echinocandin resistance mechanisms. Disk diffusion and microdilution assays were performed strictly according to CLSI documents M44-A2 and M27-A3. Eighty-nine clinical Candida isolates were included: Candida albicans (20 isolates/10 mutants), C. glabrata (19 isolates/10 mutants), C. dubliniensis (2 isolates/1 mutant), C. krusei (16 isolates/3 mutants), C. parapsilosis (14 isolates/0 mutants), and C. tropicalis (18 isolates/4 mutants). Quality control strains were C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. The correlations between zone diameters and MIC results were good for both compounds, with identical susceptibility classifications for 93.3% of the isolates by applying the current CLSI breakpoints. However, the numbers of fks hot spot mutant isolates misclassified as being susceptible (S) (very major errors [VMEs]) were high (61% for caspofungin [S, ≥11 mm] and 93% for micafungin [S, ≥14 mm]). Changing the disk diffusion breakpoint to S at ≥22 mm significantly improved the discrimination. For caspofungin, 1 VME was detected (a C. tropicalis isolate with an F76S substitution) (3.5%), and for micafungin, 10 VMEs were detected, the majority of which were for C. glabrata (8/10). The broadest separation between zone diameter ranges for wild-type (WT) and mutant isolates was seen for caspofungin (6 to 12 mm versus -4 to 7 mm). In conclusion, caspofungin disk diffusion testing with a modified breakpoint led to excellent separation between WT and mutant isolates for all Candida species.
目前,CLSI 已经对药敏纸片扩散法检测进行了标准化,并且已经确定了几种抗真菌药物的药敏折点。对于卡泊芬净,批准使用 5μg 药敏纸片,而对于米卡芬净,正在评估 10μg 药敏纸片。我们使用一组已知具有棘白菌素耐药机制的和无耐药机制的念珠菌分离株,评估了卡泊芬净和米卡芬净药敏纸片检测的性能。药敏纸片扩散法和微量稀释法均严格按照 CLSI 文件 M44-A2 和 M27-A3 进行。共纳入 89 株临床分离的念珠菌:白念珠菌(20 株/10 株突变株)、光滑念珠菌(19 株/10 株突变株)、都柏林念珠菌(2 株/1 株突变株)、克柔念珠菌(16 株/3 株突变株)、近平滑念珠菌(14 株/0 株突变株)和热带念珠菌(18 株/4 株突变株)。质控菌株为近平滑念珠菌 ATCC 22019 和克柔念珠菌 ATCC 6258。对于两种药物,抑菌环直径与 MIC 结果之间的相关性都很好,应用当前 CLSI 折点,93.3%的分离株具有相同的药敏分类。然而,棘白菌素热点突变株分离株被错误分类为敏感(S)(非常大误差[VME])的数量很高(卡泊芬净 61%[S,≥11mm]和米卡芬净 93%[S,≥14mm])。将药敏纸片扩散法的折点改为 S(≥22mm)可显著提高区分度。对于卡泊芬净,检测到 1 个 VME(一株 F76S 取代的热带念珠菌)(3.5%),对于米卡芬净,检测到 10 个 VME,其中大部分为光滑念珠菌(8/10)。野生型(WT)和突变型分离株之间抑菌环直径范围的分离最宽的是卡泊芬净(6 至 12mm 与-4 至 7mm)。总之,对于所有念珠菌属,卡泊芬净药敏纸片扩散法检测的改良折点可使 WT 和突变株分离株之间有很好的区分。